Dermasensor, a handheld AI device, can help physicians screen for skin cancer
Dermatologist Rebecca Hartman, MD, MPH, explains how DermaSensor is designed to scan and assess skin lesions to aid cancer screening efforts.
The first health care professional to examine a skin lesion that appears suspicious to a patient is most frequently the primary care clinician. Whether the lesion is of greater concern than a normal dermatologic variation or perhaps an age-related change will be the frontline clinician's next assessment, followed by a decision to watch or to make a referral to a specialist.
In an interview with partner brand, Patient Care® dermatologist Rebecca Hartman, MD, MPH, described DermaSensor, a new FDA-approved handheld, AI-based device designed to scan and assess skin lesions in the primary care clinical setting. The device returns 1 of 2 responses following a scan: “Investigate Further,” indicating a referral, or “Monitor,” an outcome which could help rule out a majority of unnecessary referrals for benign lesions.
© Dermasensor
In the short video above, Hartman describes the device technology and highlights its sensitivity and specificity when used in primary care.
FDA issues de novo clearance for SonoMotion’s Stone Clear device, for kidney stone treatment
Stone Clear is the first and only device cleared by the FDA that uses external ultrasound pulses to facilitate passage of post-lithotripsy kidney stone fragments without surgery.
